TMCO1, as a potential biomarker of prognosis and immunotherapy response, regulates head and neck squamous cell carcinoma proliferation and migration
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Transmembrane and coiled-coil domains 1 (TMCO1) impacts head and neck cancer progression. High TMCO1 expression correlates with poor survival, suggesting TMCO1 as a therapeutic target for head and neck squamous cell carcinoma (HNSCC).
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Transmembrane and coiled-coil domains 1 (TMCO1) regulates intracellular calcium and is linked to poor cancer prognosis.
- TMCO1's role in head and neck squamous cell carcinoma (HNSCC) requires further investigation.
Purpose Of The Study
- To evaluate TMCO1 as a prognostic biomarker and therapeutic target in HNSCC.
- To elucidate the functional mechanisms of TMCO1 in HNSCC progression.
Main Methods
- Analysis of TMCO1 expression data from TCGA and other databases.
- Immunohistochemical staining for TMCO1 verification.
- In vitro experiments to assess TMCO1's effect on HNSCC cell behavior.
- Bioinformatic analyses including nomogram, ROC curve, Gene Ontology, and gene network analysis.
Main Results
- High TMCO1 expression is significantly associated with poorer HNSCC survival and advanced tumor progression.
- TMCO1 promotes proliferation, migration, invasion, adhesion, and clonal formation of HNSCC cells.
- Low TMCO1 expression indicates better suitability for immunotherapy and guides chemotherapy drug selection.
Conclusions
- TMCO1 is a reliable prognostic biomarker and potential therapeutic target for HNSCC.
- TMCO1 influences HNSCC cell behavior and interacts with the tumor microenvironment.
- Targeting TMCO1 offers potential for precision oncology strategies in HNSCC treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.